Gemcitabine Integrated Nano-Prodrug Carrier System

Area of Science:

• Biomaterials Science
• Nanotechnology
• Drug Delivery

Background:

• Peptide nanomaterials offer advantages like biodegradability and biocompatibility for drug delivery.
• Gemcitabine, a breast cancer drug, suffers from rapid degradation and poor release kinetics.
• Hydrophilic drugs like gemcitabine present challenges in nanocarrier encapsulation and sustained release.

Purpose of the Study:

• To design a novel peptide prodrug of gemcitabine for enhanced stability and targeted delivery.
• To develop a self-assembled peptide nanocarrier system for improved gemcitabine therapeutic efficacy.
• To evaluate the drug release profile and in vitro anticancer activity of the gemcitabine-loaded nanocarrier.

Main Methods:

• Covalent conjugation of gemcitabine to Fmoc-protected glycine to create a prodrug.
• Integration of the gemcitabine prodrug into a self-assembling nanocarrier system using oppositely charged amyloid-inspired peptides (Fmoc-AIPs).
• Characterization of the self-assembled one-dimensional nanofibers at physiological conditions.

Main Results:

• The designed peptide prodrug was successfully integrated into the nanocarrier system.
• The gemcitabine-loaded nanocarrier system demonstrated slow drug release properties.
• The system effectively reduced the viability of 4T1 breast cancer cells in a time- and concentration-dependent manner.

Conclusions:

• The developed peptide nanocarrier system shows promise for improving gemcitabine delivery in breast cancer therapy.
• Noncovalent interactions facilitate the integration of prodrugs into self-assembled peptide nanostructures.
• This approach offers a potential strategy for overcoming the limitations of hydrophilic anticancer drugs.